Janux Therapeutics
Janux Therapeutics57
About
What does Janux Therapeutics do?
Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies. Their proprietary TRACTr, TRACIr, and ARM platforms are designed to selectively modulate T cells to fight cancer and autoimmune diseases, aiming to transform patients' lives. They are currently evaluating their lead tumor-activated T cell engager (TRACTr) in a clinical trial for prostate cancer.
What is Janux Therapeutics's revenue?
StartupHub estimates Janux Therapeutics's annual revenue at $18.3M (range $9.8M to $47.8M, 68% confidence), based on comparable companies in the sector.
What is Janux Therapeutics's valuation?
StartupHub estimates Janux Therapeutics's effective valuation at $157.6M (range $58.8M to $334.1M, 43% confidence), based on comparable companies in the sector.
How much funding has Janux Therapeutics raised?
Janux Therapeutics has raised a total of $181M in funding. The most recent round on record is Series B.
Where is Janux Therapeutics headquartered?
Janux Therapeutics is headquartered in San Diego, California, USA.
When was Janux Therapeutics founded?
Janux Therapeutics was founded in 2017.
What industry does Janux Therapeutics operate in?
Janux Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Immunotherapy, Biotech, HealthTech.
How many employees does Janux Therapeutics have?
Janux Therapeutics has approximately 110 people on record.
No comments yet. Be the first to share your take.